Ͻ0.05), but this was not confirmed when only patients with breast cancer were considered.
However, free thyroxine (FT 4 ) measurements remain useful to confirm the diagnosis of thyroid diseases and to evaluate the thyroidal status when TSH measurements appear to disagree with the clinical picture, as may be the case in patients with nonthyroidal illnesses (1 ) .
Because it represents only a minute fraction of the total serum T 4 , measuring FT 4 , i.e., T 4 not bound to binding proteins, remains difficult. This is especially true for sera from patients with nonthyroidal illnesses that have an altered binding capacity (2, 3 ) . A variety of in vitro methods have been developed to estimate FT 4 . The lowmolecular weight radioactive-labeled analog method was much criticized (2 ) and was soon completely withdrawn from the market. The most widely used methods are now the two-step assay and the one-step labeled-antibody assay. The aim of our study was to compare FT 4 concentrations in sera from patients with nonthyroidal illnesses, measured with three recent nonisotopic automated techniques and with three manual RIAs: two immunoextraction assays (one two-step and one one-step assay), and a direct equilibrium dialysis (ED) assay considered as the reference method (2 ) .
The patient panel consisted of 20 hospitalized subjects on the seventh day following a bone marrow transplant, an example of severe acute illness. The bone marrow transplant was indicated for several hemopathies (n ϭ 12) or solid cancers (n ϭ 8). All patients were euthyroid before the treatment, and none had been known to have a patent thyroid dysfunction in the past. The preparation regimen before the transplant consisted of chemotherapy alone (n ϭ 11) or chemotherapy associated with total-body radiotherapy (n ϭ 9). After the transplant (allogenic in 9 cases and autogenic in 11 cases), patients received immunosuppressive drugs such as glucocorticosteroids (prednisone, 10 -20 mg/day), cyclosporin, methotrexate, and calcium folinate. They also received granulocyte growth factors, antibiotics, antiviral and antifungal drugs, low-molecular weight heparinate (1000 -10 000 units/day), and several comfort medications. All of the procedures we followed were in accordance with the Helsinki Declaration of 1975 and the subsequent 1996 amendments. The patient sera were collected for routine analysis, were kept frozen at Ϫ20°C, and were analyzed shortly after thawing.
Two automated FT 4 methods were labeled-antibody immunoassays: the electrochemiluminescent Elecsys FT 4 assay from Roche Diagnostics performed on the 2010 analyzer; and the enhanced chemiluminescent Vitros ECI FT 4 assay from Ortho-Clinical Diagnostics. The third automated assay was a non-isotope-labeled analog technique: ADVIA Centaur FrT4 from Bayer Diagnostics. The two-step RIA was the GammaCoat FT 4 from DiaSorin, and the one-step RIA was the labeled antibody kit Amerlex-MAB FT 4 from Ortho-Clinical Diagnostics. The manual direct ED technique was the Nichols FT 4 method (Nichols Institute Diagnostics). In addition to the FT 4 assays, TSH was measured using four third-generation automated immunometric assays: the Immulite TSH-3G  from Diagnostic Products Corporation performed on the  Immulite analyzer; the Elecsys TSH from Roche Diagnostics performed on the Elecsys 2010 analyzer; the Vitros   ECI TSH from Ortho-Clinical Diagnostics; and the ADVIA  Centaur TSH-3 from Bayer Diagnostics. Total T 4 was  measured with the Elecsys T 4 assay from Roche Diagnostics performed on the 2010 analyzer. The individual results of TSH and FT 4 measurements are reported in Table 1 . The FT 4 values have been plotted as the percentage of the mean reference value, determined in the laboratory from Ͼ100 euthyroid control subjects (Fig. 1 ). The TSH results obtained with the four methods were in close agreement. When a low threshold of 0.15 mIU/L was used, only one sample (patient 11) was intermethod discordant, with borderline results between 0.12 and 0.17 mIU/L. All other TSH results obtained with the four assays were concordant, yielding 8 values within the reference interval and 11 decreased values. This finding confirms the good reliability of recent TSH assays, which, as in our previous study (4 ) , classified the sera in an equivalent way. However, the Vitros ECI TSH median was lower than the three others (Wilcoxon paired-rank test, P Ͻ0.07), and as already reported with the Immulite and AxSYM TSH assays (5 ) , a negative bias between the Vitros ECI TSH results and the Elecsys, Immulite, and ADVIA Centaur TSH results was observed at low values Ͻ0.2 mIU/L.
The FT 4 value obtained with the ED technique was within the reference interval in 11 sera and increased in 9.
To study the agreement between the FT 4 results obtained with the different assays and with the dialysis technique, the percentages of concordance were calculated and the degree of concordance was measured using Cohen's kappa coefficient () (6 ) . For this purpose, FT 4 results were classified as low, normal, or high, using the reference limits of each assay. As generally accepted, concordance was judged to be very good for Ͼ0.80 and good for 0.81 Ͼ Ͼ 0.60 (7 ) . FT 4 concordance with the dialysis method was good and very good for the Vitros ECI FT 4 and the GammaCoat FT 4 , respectively (Table 1) . It was poor and not statistically significant for the Elecsys FT 4 , and there was no concordance at all ( Ͻ0) for the ADVIA Centaur and Amerlex-MAB FT 4 assays.
The dialysis method represents a fundamentally reliable approach for FT 4 measurements, although it causes a dilution (1:13 in the Nichols kit); the effect of this dilution on FT 4 determinations is difficult to assess if binding competitors are present (2 ) . The transplanted patients were heparin treated. Heparin is known to induce, in vivo, a release of lipoprotein lipase from the vascular endothelium. The lipolytic activity of this enzyme in vivo, and/or in vitro during sample storage and assay, leads to an increase in the serum concentration of nonesterified free fatty acids (NEFAs), which are binding competitors of T 4 , and consequently to an increase in FT 4 (8 ) . The production of NEFAs is negligible during storage at Ϫ20°C, but it could be particularly marked during the overnight dialysis step at 37°C. Like ED, the GammaCoat assay is based on a sound physicochemical basis, and it has been shown to give values in close agreement with those of ED in many states, such as high and low binding protein concentrations, autoantibodies, low total T 4 , and nonthyroidal illness (9 ) . Against ED, the GammaCoat assay has the advantage of involving a much shorter incubation time at 37°C (20 min instead of 16 h), which should limit the generation of NEFAs in vitro. Increased FT 4 results were also frequent with the GammaCoat assay: eight results were above the upper reference limit. Therefore, increased ED FT 4 values should not be considered an in vitro artifact resulting from prolonged dialysis at 37°C, but they may be a reflection of in vivo hyperthyroxinemia.
Among the other four FT 4 assays, only the Vitros ECI showed an acceptable concordance with ED results. This new labeled-antibody assay, like ED, has been shown to be free of biases that depend on the serum binding capacity and does not include albumin in the assay reagents to buffer the effects of NEFAs (10 ) . The other two labeled-antibody assays, the Elecsys and Amerlex-MAB, include albumin in their reagents. Albumin can induce negative biases when the serum binding capacity is reduced, as it is in sera from patients with nonthyroidal illnesses (10 ) . The ADVIA Centaur FT 4 reagents do not contain albumin. The negative bias observed with this method might be related to the sensitivity of the labeled analog to variations in serum albumin concentrations. The ADVIA Centaur analog is a high-molecular weight analog, IgG-T 4 complex labeled with acridinium ester. In general, macromolecular analogs are not considered albumin-dependent, and they do not have the marked drawbacks of low-molecular weight radioactive analogs (11 ) . However, it has been shown that, contrary to the Vitros ECI, the Chiron ACS:180 FT 4 , a previous formulation of ADVIA Centaur reagents, yielded decreased FT 4 values when the serum binding capacity was reduced by dilution (5, 12 ) and yielded only moderately increased FT 4 values when a competitor such as furosemide was added to serum (13 ) . Our results are consistent with the sensitivity of the ADVIA Centaur assay to the serum binding capacity. The dependence on the serum binding capacity of the ADVIA Centaur kit, the Amerlex-MAB kit, and to a lesser extent the Elecsys kit, may also explain the decreased FT 4 measurements observed with these three kits: the number of FT 4 results below the lower limit of the reference interval for each kit were three, four, and one, respectively. TSH results were frequently decreased, and FT 4 values obtained with the ED technique, GammaCoat, and Vitros ECI kits were frequently increased. However, the concordance between the Elecsys TSH results, chosen as example, and FT 4 determined with these three kits was poor: the percentages of concordance were between 60% and 65%; and the coefficient, lying between 0.24 and 0.33, was not statistically significant ( Table 1 ). The concordance was still lower with Elecsys FT 4 and absent ( Ͻ0) with the ADVIA Centaur and the Amerlex-MAB FT 4 . The relationship between serum TSH and FT 4 has been well characterized in individuals with normal hypothalamic and pituitary functions and stable concentrations of thyroid hormones. The poor degree of agreement between the FT 4 and TSH values in our study might be attributable in part to transient hyperthyroxinemia that did not last long enough to induce a decrease in TSH to Ͻ0.15 mIU/L. Transient hyperthyroxinemia may lead to high FT 4 concentrations with TSH concentrations within the reference interval. One reason for the discordant low TSH values in the presence of FT 4 values within the reference interval may be related to the glucocorticoid treatment in these patients, which decreases TSH secretion and lowers serum TSH concentration without decreasing FT 4 below the lower limit of the reference interval (14 ) . Finally, the discordance between TSH values within the reference interval and decreased FT 4 values may be attributed to the negative bias of the Amerlex-MAB, ADVIA Centaur, and Elecsys FT 4 assays. This bias might be related to decreased serum binding capacity. The poor concordance we observed between TSH and FT 4 might also be related to the impairment of the hypothalamic pituitary thyroid axis in a critical situation such as bone marrow transplant.
In conclusion, despite a negative bias of the Vitros ECI TSH at concentrations Ͻ0.2 mIU/L, the concordance between all TSH methods was good in bone marrowtransplanted patients. The FT 4 concentrations measured with recent automated methods were not equivalent. Among the three automated methods studied, which may gain widespread use, only the Vitros ECI showed a good concordance with the ED and GammaCoat kits, which frequently gave increased values and which are known to be technically reliable assays (2, 9 ) . However, patients with nonthyroidal illnesses, such as those of this study, are not considered as hyperthyroid but as presenting with euthyroid sick syndrome (15 ) . They do not benefit from treatment directed at normalizing FT 4 . FT 4 results within the reference intervals were obtained in 85% of the patients with the Elecsys assay and in 80% of the patients with the ADVIA Centaur and Amerlex-MAB assays. If the "quality" of a FT 4 method, in this situation, is judged on a "to treat or not to treat" basis, FT 4 assay methods that more frequently produce values within the reference intervals, such as the Elecsys, ADVIA Centaur, and Amerlex-MAB, should be preferred. More than ever it is necessary to have a good knowledge of the FT 4 method used to correctly interpret the results of thyroid function tests in patients with nonthyroidal illnesses. This work was supported by the Hô pitaux Universitaires de Strasbourg. We thank Bayer Diagnostics and Ortho-Clinical Diagnostics for providing their TSH and FT 4 reagents free of charge. We also thank N. Heider for carefully reviewing the English in the manuscript. 
Determination of Plasma Serotonin and 5-Hydroxyindoleacetic Acid in Healthy Subjects and Cancer Patients,
Ming-Shih Lee, 1, 6 Fu-Chou Cheng, 2* Hong-Zen Yeh, 3 Tian-Yuh Liou, 4 (1, 2 ) . Plasma 5-HT is derived largely from the enteroendocrine cell in the gastrointestinal tract. The evidence of the relationships between 5-HT and these pathological conditions has been obtained mostly from studies of 5-HT and 5-hydroxyindoleacetic acid in the plasma of humans (3 ) . The most reliable laboratory test to detect a carcinoid tumor is the repeated determination of the urinary 5-HIAA (4 ). In addition, wholeblood 5-HT is increased in patients with metastatic midgut carcinoid tumors (1, 2 ) .
Liquid chromatography with electrochemical detection provides the highest sensitivity for the determination of human plasma 5-HT and/or 5-HIAA. However, widely variable "normal" concentrations of plasma 5-HT (0.5-44 g/L) have been reported (5) (6) (7) (8) (9) (10) . These inconsistencies might be attributable to variations in assay techniques or calibration or the release of 5-HT from platelets during sample preparation. In our previous study, we successfully assayed human plasma 5-HT by ultrafiltration and microbore liquid chromatography-electrochemical detection (10 ) . The objective of this study was to apply this pretreatment procedure to the measurement of plasma 5-HT and 5-HIAA in healthy subjects and cancer patients.
Blood samples from 165 healthy subjects (65 women and 100 men; age range, 25-79 years) and from 40 cancer patients (21 women and 19 men; age range, 25-76 years) were collected and centrifuged immediately to separate plasma (1000g for 20 min at 4°C). Informed consent was obtained from each person before this study. Of those patients specified as having intestinal cancers, 8 had gastric cancers and 17 had colon cancers. Two patients with early cancers (limited within submucosal layer) and 11 patients with advanced cancers received excision of the primary tumor and lymph node dissection. Twelve patients were considered unresectable because of invasion to vital organs or distant metastasis; these patients received either palliative or bypass surgery. Patients with carcinoid tumors were excluded from this study. The liquid chromatography system was composed of a Beckman 126 pump (flow rate, 50 L/min), a BAS-4C amperometric detector (set at ϩ0.75 V; Bioanalytical Systems), and a microbore column (Inertsil-2, 5-m octadecylsilane, 100 ϫ 1.0 mm; G.L. Sciences) (10 ) . The mobile phase consisted of 75 mL of acetonitrile, 5 mL of tetrahydrofuran, 2.2 mmol/L sodium 1-octanesulfonate, 14.7 mmol/L monosodium dihydrogen orthophosphate, 30 mmol/L sodium citrate, 0.027 mmol/L EDTA, and 1 mL of triethylamine in 1 liter of doubly distilled water (adjusted to pH 3.5). Plasma 5-HT and 5-HIAA were calculated by determining each peak-area ratio relative to the internal standard, 3-methoxytyramine. Statistical evaluation was performed using unpaired Student t-tests, and P Ͻ0.05 was accepted as significant.
Plasma 5-HT and 5-HIAA concentrations in the 165 healthy individuals were 0.62 Ϯ 0.11 and 1.94 Ϯ 0.09 g/L (mean Ϯ SE), respectively ( Table 1 ). The plasma 5-HT concentrations (6.26 Ϯ 1.59 g/L) in cancer patients (both intestinal cancer and hepatoma; n ϭ 40) were significantly higher (P Ͻ0.05) when compared with healthy subjects. The plasma 5-HT concentrations of patients with intestinal cancer (n ϭ 25) were significantly higher (6.96 Ϯ 2.26 g/L) when compared with healthy subjects. Lembeck (11 ) reported increased plasma 5-HT in a patient with carcinoid tumor. The secretion rate of 5-HT by a carcinoid tumor could exceed the maximum uptake capacity of platelets, leading to increased plasma 5-HT (12, 13 ) . Thus, the 5-HT produced by the tumor might first occupy all available binding sites on platelets before circulating as free plasma 5-HT. However, the 5-HT concentrations decreased dramatically to 1.96 Ϯ 0.78 g/L after surgery to remove cancer cells from patients with intestinal cancer (n ϭ 13). Our data suggested that removing these cancer cells from patients might limit the production of circulating 5-HT. The plasma 5-HIAA concentrations did not change significantly after surgery in the above intestinal cancer patients. However, Page et al. (14 ) demonstrated 
